文献速递眼底病与葡萄膜炎

雷珠单抗与阿柏西普治疗新生血管性年龄相关性黄斑变性的治疗结局:来自Fight Retinal Blindness!登记研究的数据

Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry.
PubMed 文献 · Ophthalmology · 2019-10-11

该研究基于Fight Retinal Blindness!前瞻性设计观察性登记数据库,回顾性分析2013年12月1日至2015年12月31日期间开始治疗的新生血管性年龄相关性黄斑变性初治眼,比较雷珠单抗与阿柏西普治疗3年的视力结局和治疗频率。结果显示两组3年视力变化和治疗频率均相似,雷珠单抗组向阿柏西普转换更多,结论为两种药物在视力结局和治疗频率方面均无优势。

要点

  • 雷珠单抗组与阿柏西普组3年时所有眼粗平均视力变化相似(+1.5字母 vs +1.6字母,P=0.97)。
  • 两组中位注射次数均为18次,中位临床访视次数均为21次。
  • 3年内脉络膜新生血管判为活动性的调整访视比例两组相似(雷珠单抗43% vs 阿柏西普51%,P=0.9)。

核心结论

  • 在3年视力结局和治疗频率方面,雷珠单抗与阿柏西普治疗新生血管性年龄相关性黄斑变性均无优势。

研究设计与样本

  • 回顾性分析前瞻性设计的观察性结局登记数据库Fight Retinal Blindness!的数据。
  • 纳入2013年12月1日至2015年12月31日期间开始治疗的新生血管性年龄相关性黄斑变性初治眼,接受雷珠单抗或阿柏西普并在登记数据库中追踪。
  • 共纳入897例患者的965只眼(雷珠单抗499只眼[469例患者];阿柏西普466只眼[432例患者])。

主要发现

  • 3年时所有眼粗平均视力变化:雷珠单抗组+1.5字母(95%CI 0-3.1字母),阿柏西普组+1.6字母(95%CI -0.2至3.3字母;P=0.97),两组相似。
  • 3年时所有眼调整平均视力变化:雷珠单抗组+0.3字母(95%CI -1.5至2.0字母)vs 阿柏西普组+1.0字母(95%CI -0.7至2.8字母;P=0.66)。
  • 两组均接受中位18次注射,来自中位21次临床访视。
  • 3年内脉络膜新生血管判为活动性的调整访视比例:雷珠单抗组43% vs 阿柏西普组51%(P=0.9),两组相似。
  • 雷珠单抗向阿柏西普转换多于反向转换(P<0.001);两组未完成3年治疗的眼比例相似(P=0.21)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Ranibizumab and aflibercept are both approved for the treatment of neovascular age-related macular degeneration (nAMD). Herein, we compare the 3-year treatment outcomes of the 2 in routine clinical practice. DESIGN: Retrospective analysis of data from a prospectively designed observational outcomes registry, the Fight Retinal Blindness! PARTICIPANTS: Treatment-naïive eyes starting nAMD treatment from December 1, 2013 through December 31, 2015, with either ranibizumab or aflibercept that were tracked in the registry. METHODS: Visual acuity (VA) was analyzed annually in completers (those who completed 3 years of treatment) and in all eyes (completers, noncompleters, and those who switched treatment ). MAIN OUTCOME MEASURES: The primary outcome was mean change in VA (number of letters read on a logarithm of the minimum angle of resolution chart). RESULTS: A total of 965 eyes of 897 patients (ranibizumab, 499 eyes [469 patients]; aflibercept, 466 eyes [432 patients) were identified. The mean VA and the type of the choroidal neovascularization (CNV) at the start of treatment were similar between the 2 groups. The group receiving ranibizumab was older. The crude mean VA change of +1.5 letters (95% confidence interval [CI], 0-3.1 letters) in the ranibizumab group and of +1.6 letters (95% CI, -0.2 to 3.3 letters; P = 0.97) in the aflibercept group at 3 years in all eyes was similar, as was the adjusted mean VA change, +0.3 letters (95% CI, -1.5 to 2.0 letters) versus +1.0 letters (95% CI, -0.7 to 2.8 letters; P = 0.66). Both treatment groups received a median of 18 injections from a median of 21 clinical visits. The adjusted proportion of clinical visits when the CNV was graded active over 3 years was similar between ranibizumab (43%) and aflibercept (51%; P = 0.9). More switches from ranibizumab to aflibercept (P < 0.001) took place than vice versa. The proportion of eyes that did not complete 3 years of treatment in each of the group was similar (P = 0.21). CONCLUSIONS: Neither ranibizumab nor aflibercept was superior to the other in terms of VA outcomes and treatment frequency at 3 years for nAMD.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Bhandari S, Nguyen V, Arnold J, et al. Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry. Ophthalmology. 2019. PMID: 31757494. doi:10.1016/j.ophtha.2019.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。